BioCentury
ARTICLE | Company News

Boehringer Ingelheim, Medivir deal

August 11, 2014 7:00 AM UTC

Boehringer Ingelheim granted Medivir exclusive, worldwide rights to develop and commercialize compounds that inhibit the RSV fusion protein to treat and prevent respiratory syncytial virus (RSV) infec...